• Medientyp: E-Artikel
  • Titel: Curcumin inhibits acute pulmonary embolism and inflammation by inhibiting high mobility group box 1 (HMGB1)
  • Beteiligte: Wang, Min; Yu, Xinming; Tao, Lili; Cui, Xiaowen
  • Erschienen: American Scientific Publishers, 2023
  • Erschienen in: Materials Express, 13 (2023) 5, Seite 839-845
  • Sprache: Englisch
  • DOI: 10.1166/mex.2023.2418
  • ISSN: 2158-5849
  • Schlagwörter: General Materials Science
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>This study assessed the role of Curcumin in acute pulmonary embolism (APE) and inflammation. Male rats were assigned into sham operation group, APE group, low-dose and high-dose of Curcumin group for this study. Levels of IL-1<jats:italic>β</jats:italic>, TNF-<jats:italic>α</jats:italic>, and Interleukin-6 (IL-6) inflammatory indicators were analyzed, including also, pathological changes of lung tissue. We also assessed High mobility group box 1 (HMGB1), receptor for advanced glycation end product (RAGE) and Nuclear factor kappa B (NF-<jats:italic>κ</jats:italic>B) protein expressions. Results showed that, inflammation indicators were reduced after treatment at 6 h, 24 h, and 72 h, when compared with APE group, but were still higher than sham operation group (<jats:italic>P</jats:italic> &lt;0.05). Serum inflammation index was higher at 2 h after modeling (<jats:italic>P</jats:italic> &lt;0.05). Moreover, treatment groups showed continuously reduced HMGB1 protein expression, with lower level of HMGB1 in high dose group (<jats:italic>P</jats:italic> &lt;0.05). RAGE expression continued to increase in APE and treatment groups (<jats:italic>P</jats:italic> &lt;0.05). However, its level in treatment groups was lower than APE group (<jats:italic>P</jats:italic> &lt;0 05). The NF-KB expression continued to increase in APE and treatment groups (<jats:italic>P</jats:italic> &lt;0.05) with a lower level in treatment group (<jats:italic>P</jats:italic> &lt;0.05). Curcumin effectively suppressed inflammatory response in acute pulmonary embolism, by reducing RAGE/NF-KB signal activity and inhibiting inflammatory response by inhibiting HMGB1 expression.</jats:p>
  • Zugangsstatus: Freier Zugang